miR-1271-5p inhibits cell proliferation and induces apoptosis in acute myeloid leukemia by targeting ZIC2

XIAOHE CHEN, SHOUHANG YANG, JUE ZENG and MING CHEN

Department of Blood Transfusion, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, Zhejiang 325200, P.R. China

Received March 21, 2018; Accepted November 1, 2018

DOI: 10.3892/mmr.2018.9680

Abstract. MicroRNAs (miRNAs) have been demonstrated to regulate the progression of numerous types of cancer, including acute myeloid leukemia (AML). Previous studies demonstrated that miR‑1271‑5p functions as a tumor suppressor; however, the roles of miR‑1271‑5p in AML remain unknown. In the present study, miR‑1271‑5p was significantly downregulated in AML tissues compared with normal tissues by reverse transcription‑quantitative polymerase chain reaction analysis. Furthermore, the expression levels of miR‑1271‑5p in patients with AML may function as a prognostic marker. In addition, overexpression of miR‑1271‑5p significantly suppressed the proliferation and induced apoptosis of AML cells by Cell Counting kit‑8 and fluorescence activated cell sorter assays; miR‑1271‑5p downregulation exhibited opposing effects. Additionally, transcription factor ZIC2 may be a direct target of miR‑1271‑5p in AML cells, which was demonstrated by a luciferase reporter assay and RNA pulldown assay. Overexpression of miR‑1271‑5p significantly reduced the mRNA and protein expression levels of ZIC2 in AML193 and OCI‑AML2 cells by reverse transcription‑quantitative polymerase chain reaction analysis and western blotting. Furthermore, an inverse correlation between miR‑1271‑5p and ZIC2 expression in AML samples was observed. In summary, ZIC2 was upregulated in AML tissues, and restoration of ZIC2 expression was able to promote the proliferation and reduce the apoptosis of AML cells transfected with miR‑1271‑5p mimics. The results of the present study demonstrated that miR‑1271‑5p inhibited the progression of AML by targeting ZIC2.

Introduction

Acute myeloid leukemia (AML) is a highly heterogeneous and malignant hematological tumor characterized by the accumulation of undifferentiated myeloid progenitor cells in the bone marrow and peripheral blood (1). At present, chemotherapy and stem cell transplantation are the principal therapeutic approaches for AML (2); however, the outcomes of patients with AML at advanced stage with metastasis and recurrence remain poor (3). Genetic mutations and aberrant expression levels of cancer‑associated genes may induce AML (4,5). A previous study demonstrated that impaired expression of Wilms tumor 1, high meningioma 1 and ETS‑related gene is associated with the clinical outcomes of AML (6). In addition, a number of microRNAs (miRNAs/miRs) have been reported to be involved in the progression of AML, including miR‑19b and miR‑375 (7,8); however, the underlying molecular mechanisms remain unknown.

miRNAs are a group of short noncoding RNAs with a length of ~21 nucleotides (9). A recent study has identified that miRNAs serve essential roles in regulating gene expression by binding to the target sequence and promoting the degradation of specific mRNAs (10). miRNAs regulate various biological processes in cancer cells, including cell differentiation, proliferation, metastasis and apoptosis (11,12). A variety of miRNAs are aberrantly expressed in various types of cancer, including AML (13,14). In AML, numerous miRNAs are dysregulated (15). Ding et al (16) identified that upregulated miR‑130a may induce cell death in AML. Zhao et al (17) demonstrated that miR‑144 is a potential non‑invasive biomarker for patients with AML. Ma et al (14) identified that miR‑362‑5p is a novel prognostic predictor of cytogenically normal AML. Although the importance of miRNAs in AML has been identified, the underlying mechanisms remain unknown.

Recent studies have demonstrated that miR‑1271‑5p is involved in the pathogenesis of colorectal cancer and hepatocellular carcinoma (18,19); however, whether miR‑1271‑5p may regulate the progression of AML remains unknown. In the present study, miR‑1271‑5p inhibited the proliferation and induced apoptosis in AML via targeting zinc family member 2 (ZIC2), which suggested that miR‑1271‑5p may be a promising therapeutic target for the treatment of patients with AML.

Correspondence to: Dr Ming Chen, Department of Blood Transfusion, The Third Affiliated Hospital of Wenzhou Medical University, 108 Wansong Road, Ruian, Zhejiang 325200, P.R. China E‑mail: mingchen033@163.com

Key words: microRNA-1271-5p, Zic family member 2, proliferation, apoptosis, acute myeloid leukemia
Materials and methods

Clinical specimens. The peripheral blood samples (50 ml per sample) were obtained from patients with AML (n=35) and healthy donors (n=35) at The Third Affiliated Hospital of Wenzhou Medical University (Wenzhou, China) between January 2014 and December 2016. The sex ratio of the patients and controls was 1:1 and the patients were aged between 2 and 60 years old. Patients were diagnosed with AML according to the pathological and clinic features of the disease (20). Patients who received chemotherapy or radiotherapy prior to collection were excluded; all other patients with AML were included. Informed consent was obtained from each patient, and the present study was approved by the Institutional Ethics Committee of The Third Affiliated Hospital of Wenzhou Medical University. The patients with AML were divided into miR-1271-5p high expression and low expression groups according to the median value of miR-1271-5p expression.

Cell culture and transfection. AML cell lines (HL-60, Kasumi-1, AML193 and OCI-AML2) and a normal cell line derived from marrow stroma (HS-5) were purchased from The American Type Culture Collection (Manassas, VA, USA) and cultured in Eagle's minimum essential medium (Gibco; Thermo Fisher Scientific, Inc). Cells were cultured in 6-well plates and cultured with Eagle's minimum essential medium at 37˚C overnight and subsequently transfected with 50 nM miR-1271-5p mimics (5'‑CUUGGACCUCUAAGCAAGCA CUCA-3'), inhibitors (5'‑UGAGUGCCUUGCUAGGGUCCAA G-3') or the controls (5'‑UCACAACCUCUAGAAGAGU AGA-3') or pcDNA3-ZIC2 vector (1 µg; Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C in a humidified incubator containing 5% CO2.

The ZIC2 coding sequence was constructed in a pcDNA3 vector. For cell transfection, 5x10⁴ AML cells were seeded in 6-well plates and cultured with Eagle's minimum essential medium at 37˚C overnight and subsequently transfected with 50 nM miR-1271-5p mimics (5'‑CUUGGACCUCUAAGCAAGCA CUCA-3'), inhibitors (5'‑UGAGUGCCUUGCUAGGGUCCAA G-3') or the controls (5'‑UCACAACCUCUAGAAGAGU AGA-3') or pcDNA3-ZIC2 vector (1 µg; Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C in a humidified incubator containing 5% CO₂.

Cell proliferation assay. In total, 2x10⁴ AML193 and OCI-AML2 cells were transfected for 24 h and seeded in 96-well plates followed by incubation at 37˚C for 1, 3 and 5 days. A total of 10 µl Cell Counting kit-8 (CCK-8) reagent (Beyotime Institute of Biotechnology, Haimen, China) was added to the medium and incubated for 2 h; the absorbance at 450 nm was measured using an ELISA reader (Molecular Devices, LLC; Sunnyvale, CA, USA).

Cell cycle and apoptosis analyses. For cell cycle analysis, 2x10⁶ AML193 and OCI-AML2 cells were washed and resuspended in PBS solution containing 0.04 mg/ml propidium iodide (Invitrogen; Thermo Fisher Scientific, Inc.) and 100 mg/ml RNase (Invitrogen; Thermo Fisher Scientific, Inc.) for 15 min on ice. The samples were analyzed with a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) using the CELLQuest program 5.1 (BD Biosciences) followed by incubation at room temperature for 30 min. Modfit software 5.0 (Verity Software House, Inc., Topsham, ME, USA) was used to generate a histogram to determine the number of cells in each phase of the cell cycle.

For apoptosis analysis, 2x10⁶ AML cells were transfected with miR-1271-5p mimics, inhibitors or controls for 24 h. Cells were collected by centrifugation at 2,500 x g for 2 min at 4˚C. Apoptosis analysis was performed using an Annexin V-FITC Apoptosis Detection kit II (BD Biosciences) according to the manufacturer's protocol. Cells were analyzed by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences). The data were analyzed using Flowjo 7.6.1 (BD Biosciences).

RT-qPCR. Total RNA was extracted from cultured cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol, and cDNA was synthesized from total RNA with a PrimerScript RT Reagent kit (Takara Bio, Inc., Ostu, Japan) according to the manufacturer's protocol. The conditions were as follows: Incubation for 1 h at 42˚C and inactivation at 70˚C for 15 min. miRNA from total RNA was reverse transcribed using the Prime-Script miRNA cDNA Synthesis kit (Takara Bio, Inc.) according to the manufacturer's protocol. qPCR was performed using SYBR green Premix Ex Taq II (Takara Bio, Inc.) on a Step One Plus Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The PCR thermocycling conditions were as follows: 95˚C for 30 sec, followed by 40 cycles of 95˚C for 5 sec and 60˚C for 34 sec. GAPDH and U6 were used as the endogenous controls for mRNA and miRNA expression levels irrespectively. Relative gene expression was calculated using the 2-∆∆Cq method (21). A total of three repeats were performed. The primer sequences were: U6 (forward, 5'-CTTCGCTTCGGCACAGCATATACT-3' and reverse, 5'-ACG CTTCAGAGTTTGCGGTCT-3'), GAPDH (forward, 5'-TCA ACAACCTTTGTCAGCTCA-3' and reverse, 5'-GCTGTGT GTGTCAGGGGTCTTACT-3'), miR-1271-5p (forward, 5'-CTT GGCACCTAGAACGCTCA-3' and reverse, 5'-GCCAGAC AGACGAATAAAGACG-3') and ZIC2 (forward, 5'-GTCCGAC ACCTCCGATAAGCC-3' and reverse, 5'-CTCATGGGAC TT CATGTGCT-3').

RNA pulldown assay. Purified synthesized RNAs (Invitrogen; Thermo Fisher Scientific, Inc.) were labeled using biotin with Pierce RNA 3' End Desthiobiotinylation kit (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. A positive control (biotin-labeled wild-type miR-1271-5p, biotin-miR-1271-5p) or negative controls (5'-UCACAACCUCUCUAGAAGAGUAGA-3') were incubated with AML cell lysates from 1x10⁶ AML cells, isolated using lysis buffer (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), at 4˚C overnight. The Streptavidin magnetic beads (Sigma-Aldrich; Merck KGaA) were washed and resuspended in PBS solution containing 0.04 mg/ml propidium iodide (Invitrogen; Thermo Fisher Scientific, Inc.) and 100 mg/ml RNase (Invitrogen; Thermo Fisher Scientific, Inc.) for 15 min on ice. The samples were analyzed with a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) using the CELLQuest program 5.1 (BD Biosciences) followed by incubation at room temperature for 30 min. Modfit software 5.0 (Verity Software House, Inc., Topsham, ME, USA) was used to generate a histogram to determine the number of cells in each phase of the cell cycle.

For apoptosis analysis, 2x10⁶ AML cells were transfected with miR-1271-5p mimics, inhibitors or controls for 24 h. Cells were collected by centrifugation at 2,500 x g for 2 min at 4˚C. Apoptosis analysis was performed using an Annexin V-FITC Apoptosis Detection kit II (BD Biosciences) according to the manufacturer's protocol. Cells were analyzed by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences). The data were analyzed using Flowjo 7.6.1 (BD Biosciences).
**Western blotting.** Proteins were extracted from AML cells using radioimmunoprecipitation lysis buffer (0.15 mM NaCl, 0.05 mM Tris-HCl, pH 7.5, 1% Triton, 0.1% SDS, 0.1% sodium deoxycholate and 1% NP40). The concentration of proteins was measured using the Bradford method. A total of 20 µg total protein extract was electrophoresed on 12% SDS-PAGE and transferred by electroblotting onto polyvinylidene fluoride membranes. The membranes were blocked for 1 h at 37°C in 5% (w/v) nonfat milk prior to incubation with appropriate dilutions of the primary antibodies against ZIC2 (1:2,000; cat. no. Z4525; Sigma-Aldrich; Merck KGaA) and GAPDH (1:2,000; cat. no. 5174; Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C overnight. The membranes were subsequently incubated with horseradish peroxidase-conjugated secondary antibody (1:5,000; cat. no. ab7090; Abcam, Cambridge, UK) at 25°C for 1 h. The signals were visualized using an enhanced chemiluminescence kit (Beyotime Institute of Biotechnology) according to the manufacturer's protocol.

**Luciferase reporter assay.** The potential targets of miR-1271-5p were predicted by TargetScan 7.0 (http://www.targetscan.org/vert_71u) and miRBase (http://www.mirbase.org/search.shtml). The sequence of ZIC3-3’UTR containing the wild-type or mutant potential binding site for miR1271-5p were inserted into the SpeI and HindIII sites in the pMIR-Report vector (Ambion; Thermo Fisher Scientific, Inc.) to generate the reporter plasmid. miR-1271-5p mimic (50 nM) or inhibitor, reporter plasmid (1 µg) and pRL-CMV Renilla luciferase reporter (1 ng; Ambion; Thermo Fisher Scientific, Inc.) were co-transfected into the cells using Lipofectamine® 2000 according to the manufacturer's protocol. Luciferase activity was assayed at 48 h post-transfection using a Dual-Luciferase® Reporter Assay (Promega Corporation, Madison, WI, USA), and the levels of firefly luciferase activity were normalized to that of Renilla luciferase.

**Statistical analysis.** All statistical analyses were performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA). The results are expressed as the mean ± standard deviation. A Student's t-test or one-way analysis of variance followed by Tukey's post hoc test was used to analyze the difference in two or multiple groups. Pearson's correlation coefficient analysis was used to determine the correlations. The effect of miR-1271-5p expression on overall survival was analyzed by Kaplan-Meier analysis and a log-rank test. The experiments were repeated three times. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**miR-1271-5p is downregulated in AML samples.** To examine the cellular functions of miR-1271-5p in AML, the expression levels of miR-1271-5p in the blood of patients with AML were evaluated by RT-qPCR. The expression levels of miR-1271-5p were significantly downregulated in AML samples compared with normal samples (P<0.05; Fig. 1A). In addition, miR-1271-5p expression levels were significantly reduced in AML cell lines compared with in the normal cell line HS-5 (P<0.05; Fig. 1B). The downregulation of miR-1271-5p in AML cells may be associated with the clinical outcomes of patients with AML. Furthermore, the AML samples were divided into two groups according to the mean value of miR-1271-5p expression levels. MiR-1271-5p expression above or below the mean value were considered as high or low expression, respectively. Kaplan-Meier analysis demonstrated that patients with AML with high miR-1271-5p expression exhibited improved survival rates (Fig. 1C). These data suggested that miR-1271-5p may be involved in the progression of AML.

**miR-1271-5p inhibits AML cell proliferation and induces apoptosis.** To determine the effects of miR-1271-5p on AML cells, gain- and loss-of-function studies were performed in AML193 and OCI-AML2 cells transfected with miR-1271-5p mimics or inhibitors. RT-qPCR analysis demonstrated that, compared with the control, miR-1271-5p was significantly up- or downregulated in AML193 and OCI-AML2 cells following transfection with mimics and inhibitors, respectively (P<0.05; Fig. 2A). A CCK-8 assay and flow cytometry were used to analyze the effects of miR-1271-5p on cell proliferation and the cell cycle. The results indicated that, compared with the control, miR-1271-5p overexpression significantly inhibited the proliferation of AML cells and reduced the number of cells in S phase, and vice versa (P<0.05; Fig. 2B and C). Additionally, flow cytometry indicated that, compared with the control,
miR-1271-5p overexpression significantly promoted the apoptosis of AML cells, and vice versa (P<0.05; Fig. 2D). These results demonstrated that miR-1271-5p serves as a tumor suppressor in the progression of AML.

ZIC2 is a target of miR-1271-5p in AML cells. To identify the target genes of miR-1271-5p in AML cells, bioinformatics analysis was conducted using online software (TargetScan 7.0 and miRBase). The results identified that transcription factor ZIC2 was a possible target gene of miR-1271-5p. There was a potential binding site of miR-1271-5p in the 3'-untranslated region of ZIC2 mRNA (Fig. 3A). To determine the interaction between miR-1271-5p and ZIC2, a luciferase reporter assay was performed. The results indicated that, compared with the control, the luciferase activity of ZIC2 3'-UTR (wild-type, WT) in AML193 and OCI-AML2 cells were significantly reduced and increased by transfection with miR-1271-5p mimics and inhibitors, respectively (Fig. 3B); however, a mutation in the binding site of miR-1271-5p in ZIC2 3'-UTR (wild-type, WT) in AML193 and OCI-AML2 cells were significantly reduced and increased by transfection with miR-1271-5p mimics and inhibitors, respectively (Fig. 3B). Furthermore, an RNA pulldown assay was performed using FOXK2 as a positive control (19). The results indicated that biotin-miR-1271-5p significantly promoted the precipitation of ZIC2 and FOXK2 mRNA in AML cells compared with the control (P<0.05; Fig. 3B). Consistently, ZIC2 was additionally upregulated in AML cell lines compared with the normal cell line, HS-5 (Fig. 4B). Furthermore, RT-qPCR analysis indicated that ZIC2 was negatively correlated with miR-1271-5p in AML tissues (Fig. 4C). These results suggested that ZIC2 may be regulated by miR-1271-5p and serve an important role in AML.

Restoration of ZIC2 reverses the effects of miR-1271-5p overexpression on the proliferation and apoptosis of AML cells. The functions of ZIC2 in AML remain unknown. The present study investigated the functions of ZIC2 and whether miR-1271-5p inhibits the progression of AML by regulating ZIC2; the expression of ZIC2 was restored in AML193 and OCI-AML2 cells transfected with miR-1271-5p. RT-qPCR analysis demonstrated that ZIC2 expression was significantly upregulated in AML193 and OCI-AML2 cells following transfection with an overexpression plasmid compared with the control (Fig. 5A). The results of CCK-8 and flow cytometry analyses indicated that, compared with the control, restoration of ZIC2 significantly rescued the proliferation and reduced apoptosis in AML193 and AML2 cells, and vice versa, compared with the control; a notable decrease in ZIC2 protein expression was observed in response to miR-1271-5p overexpression (P<0.05; Fig. 3D and E).
OCI-AML2 cells transfected with miR-1271-5p (Fig. 5B-D). In summary, these data suggested that miR-1271-5p regulated the progression of AML by targeting ZIC2.

**Discussion**

A recent study revealed that numerous miRNAs were aberrantly expressed in AML (22). For example, Tian et al (23) demonstrated that miR-494 was downregulated, and suppresses bone marrow stromal cell-mediated drug resistance in AML cells. Wang et al (12) demonstrated that miR-183 is upregulated and promotes cell proliferation by regulating programmed cell death 6 in pediatric AML. Yang et al (24) identified that downregulated miR-34c was associated with poor outcome in de novo AML. Jiang et al (25) observed that miR-22 is downregulated in AML and has a notable anti-tumor role with therapeutic potential. A recent study identified that miR-1271-5p suppressed the progression of colorectal cancer (18). Another previous study suggested that miR-1271-5p inhibited cell growth by targeting FOXK2 in hepatocellular carcinoma (19); however, the functions of miR-1271-5p in AML remain unknown. In the present study, the expression patterns of miR-1271-5p in AML samples and cell lines were investigated. The data indicated that miR-1271-5p was significantly downregulated in AML samples and cell lines; miR-1271-5p overexpression suppressed AML cell proliferation and induced apoptosis by directly targeting ZIC2.

ZIC2 is a member of the ZIC family of C2H2-type zinc finger proteins, which function as transcription factors and may regulate tissue specific gene expression (26). A recent study indicated that ZIC2 served oncogenic roles in human cancer, and regulated P21 protein-activated kinase 4 to promote the growth and metastasis of hepatocellular carcinoma (27). Marchini et al (28) demonstrated that ZIC2 exhibited features of an oncopgene and its overexpression strongly correlated with the clinical course of epithelial ovarian cancer. Sakuma et al (29)
identified that ZIC2 served as a prognostic marker in oral squamous cell carcinoma. Chan et al. (30) demonstrated that ZIC2 synergistically promoted Hedgehog signaling via the nuclear retention of zinc finger protein GLI1 in cervical cancer cells. In addition, recent studies demonstrated that ZIC2 regulated the progression of nasopharyngeal carcinoma (31), liver cancer (32) and bladder cancer (33); however, the functions of ZIC2 in AML remain unknown. In the present study, ZIC2 was identified as a direct target of miR-1271-5p in AML cells. Furthermore, ZIC2 was upregulated in AML samples and cell lines, which suggested that ZIC2 may serve oncogenic roles in AML. The expression level of miR-1271-5p was negatively correlated with that of ZIC2 in AML samples; however, ZIC2 mRNA may also be targeted by other miRNAs. The mechanisms underlying ZIC2-regulated proliferation and apoptosis in AML cell remain unknown. Wang et al. (33) demonstrated that ZIC2 correlated with the phosphoinositide 3-kinase/protein kinase B signaling pathway to regulate cell proliferation and apoptosis in bladder cancer. Whether ZIC2 regulates AML cells in a similar manner requires further investigation.

In summary, the present study demonstrated that miR-1271-5p was downregulated in AML cells, which may regulate cell proliferation and apoptosis by targeting ZIC2. The findings additionally indicated ZIC2 as an oncogene in AML progression, suggesting that the miR-1271-5p/ZIC2 axis may be a promising therapeutic target for the treatment of AML.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.
Authors' contributions

XC and SY collected all the acute myeloid leukemia samples. XC, SY, JZ and MC performed the experiments. MC designed the present study and drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

For the use of human samples, the present study was approved by the Institutional Ethics Committee of The Third Affiliated Hospital of Wenzhou Medical University. Written informed consent was obtained from all patients for the use of their clinical tissues.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC-BY-NC-ND 4.0) License.